Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

Abstract

The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

1 . An RNA molecule which specifically targets the cleavage of RNA encoding human fit-1 protein, wherein said RNA molecule is of length between about 14 and about 24 nucleotides and comprises sequence complementary to said fit-1 RNA or a portion thereof.  
     
     
         2 . The RNA molecule of  claim 1 , wherein said RNA molecule comprises sequence complementary to any substrate sequence found in Tables II, III, VIII or IX.  
     
     
         3 . The RNA molecule of  claim 1 , wherein said RNA molecule is single stranded.  
     
     
         4 . The RNA molecule of  claim 1 , wherein said RNA molecule comprises one or more chemically modified nucleotides.  
     
     
         5 . The RNA molecule of  claim 1 , wherein said RNA molecule comprises one or more nucleic acid backbone modifications.  
     
     
         6 . The RNA molecule of  claim 1 , wherein said RNA molecule comprises one or more nucleic acid sugar modifications.  
     
     
         7 . The RNA molecule of  claim 1 , wherein said RNA molecule comprises one or more nucleic acid base modifications.  
     
     
         8 . The RNA molecule of  claim 1 , wherein said RNA molecule is chemically synthesized.  
     
     
         9 . A composition comprising the RNA molecule of  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         10 . The RNA molecule of  claim 6 , wherein said nucleic acid sugar modification is 2′-O-methyl.  
     
     
         11 . The RNA molecule of  claim 6 , wherein said nucleic acid sugar modification is 2′-fluoro.  
     
     
         12 . The RNA molecule of  claim 6 , wherein said nucleic acid sugar modification is 2′-H.